The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial
Open accessAbstract
Importance: Induction chemotherapy followed by high-dose therapy with autologous stem cell transplant and subsequent antidisialoganglioside antibody immunotherapy is standard of care for patients with high-risk neuroblastoma, but survival rate among these patients remains low. Objective: To determine if tandem autologous transplant improves event-free survival (EFS) compared with single transplant. Design, Setting, and Participants: Patients were enrolled in this randomized clinical trial from November 2007 to February 2012 at 142 Children's Oncology Group centers in the United States, Canada, Switzerland, Australia, and New Zealand. A total of 652 eligible patients aged 30 years or younger with protocol-defined high-risk neuroblastoma were enrolled and 355 were randomized. The final date of follow-up was June 29, 2017, and the data analyses cut-off date was June 30, 2017. Interventions: Patients were randomized to receive tandem transplant with thiotepa/cyclophosphamide followed by dose-reduced carboplatin/etoposide/melphalan (n = 176) or single transplant with carboplatin/etoposide/melphalan (n = 179). Main Outcomes and Measures: The primary outcome was EFS from randomization to the occurrence of the first event (relapse, progression, secondary malignancy, or death from any cause). The study was designed to test the 1-sided hypothesis of superiority of tandem transplant compared with single transplant. Results: Among the 652 eligible patients enrolled, 297 did not undergo randomization because they were nonrandomly assigned (n = 27), ineligible for randomization (n = 62), had no therapy (n = 1), or because of physician/parent preference (n = 207). Among 355 patients randomized (median diagnosis age, 36.1 months; 152 [42.8%] female), 297 patients (83.7%) completed the study and 21 (5.9%) were lost to follow-up after completing protocol therapy. Three-year EFS from the time of randomization was 61.6% (95% CI, 54.3%-68.9%) in the tandem transplant group and 48.4% (95% CI, 41.0%-55.7%) in the single transplant group (1-sided log-rank P=.006). The median (range) duration of follow-up after randomization for 181 patients without an event was 5.6 (0.6-8.9) years. The most common significant toxicities following tandem vs single transplant were mucosal (11.7% vs 15.4%) and infectious (17.9% vs 18.3%). Conclusions and Relevance: Among patients aged 30 years or younger with high-risk neuroblastoma, tandem transplant resulted in a significantly better EFS than single transplant. However, because of the low randomization rate, the findings may not be representative of all patients with high-risk neuroblastoma. Trial Registration: ClinicalTrials.gov Identifier: NCT00567567.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L., Castel, V, Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., & Hedborg, F. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1466 · Cited by 2,294
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Cohn, S. L., Pearson, A. D. J., London, W. B., Monclair, T., Ambros, P. F., Brodeur, G. M., Faldum, A., Hero, B., Iehara, T., Machin, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6785 · Cited by 1,910
Self-citationMatthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Self-citationMatthay, K. K., Maris, J. M., Schleiermacher, G., Nakagawara, A., Mackall, C. L., Diller, L., & Weiss, W. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.78 · Cited by 1,419
Self-citationAdvances in Risk Classification and Treatment Strategies for Neuroblastoma
Pinto, N. R., Applebaum, M. A., Volchenboum, S. L., Matthay, K. K., London, W. B., Ambros, P. F., Nakagawara, A., Berthold, F., Schleiermacher, G., Park, J. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4648 · Cited by 911
Self-citationAutologous Transplantation and Maintenance Therapy in Multiple Myeloma
Palumbo, A., Cavallo, F., Gay, F., Di Raimondo, F., Ben Yehuda, D., Petrucci, M. T., Pezzatti, S., Caravita, T., Cerrato, C., Ribakovsky, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402888 · Cited by 778
Irwin, M. S., & Park, J. R. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.015 · Cited by 392
Self-citationGm, B., Pritchard, J., Berthold, F., Nl, C., Castel, V., Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., & Hedborg, F. (1994) · PubMed · Cited by 392
Ladenstein, R., Pötschger, U., Pearson, A. D. J., Brock, P., Luksch, R., Castel, V., Yaniv, I., Papadakis, V., Laureys, G., Malis, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30070-0 · Cited by 350
Kreissman, S. G., Seeger, R. C., Matthay, K. K., London, W. B., Sposto, R., Grupp, S. A., Haas-Kogan, D. A., LaQuaglia, M. P., Yu, A. L., Diller, L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70309-7 · Cited by 304
Self-citationSchmidt, M. L., Lukens, J. N., Seeger, R. C., Brodeur, G. M., Shimada, H., Gerbing, R. B., Stram, D. O., Perez, C., Haase, G. M., & Matthay, K. K. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1260 · Cited by 241
George, R. E., Li, S., Medeiros-Nancarrow, C., Neuberg, D., Marcus, K., Shamberger, R. C., Pulsipher, M., Grupp, S. A., & Diller, L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6986 · Cited by 205
Self-citationGurney, J. G., Tersak, J. M., Ness, K. K., Landier, W., Matthay, K. K., & Schmidt, M. L. (2007) · Pediatrics · doi:10.1542/peds.2007-0178 · Cited by 201
Pritchard, J., Cotterill, S. J., Germond, S. M., Imeson, J., de Kraker, J., & Jones, D. R. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20219 · Cited by 183
London, W. B., Bagatell, R., Weigel, B. J., Fox, E., Guo, D., Van Ryn, C., Naranjo, A., & Park, J. R. (2017) · Cancer · doi:10.1002/cncr.30934 · Cited by 175
Self-citationGeorge, R. E., London, W. B., Cohn, S. L., Maris, J. M., Kretschmar, C. S., Diller, L., Brodeur, G. M., Castleberry, R. P., & Look, A. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.582 · Cited by 150
Self-citationKushner, B. H., Cheung, I. Y., Modak, S. I., Kramer, K., Ragupathi, G., & Cheung, N. V. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1012 · Cited by 147
Park, J. R., Scott, J. R., Stewart, C. F., London, W. B., Naranjo, A. H., Santana, V. M., Shaw, P. J., Cohn, S. L., & Matthay, K. K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3293 · Cited by 142
Self-citationTreatment and outcomes of patients with relapsed, high‐risk neuroblastoma: Results of German trials
Simon, T., Berthold, F., Borkhardt, A., Kremens, B., Decarolis, B., & Hero, B. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22693 · Cited by 136
Garaventa, A., Parodi, S., Bernardi, B. D., Dau, D., Manzitti, C., Conte, M., Casale, F., Viscardi, E., Bianchi, M., D’Angelo, P., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.06.010 · Cited by 129
Gay, F., Engelhardt, M. M., Terpos, E., Wäsch, R., Giaccone, L., Auner, H. W., Caers, J., Gramatzki, M., van de Donk, N. W. C. J., Oliva, S., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.174573 · Cited by 128
Cohen, L. E., Gordon, J. H., Popovsky, E. Y., Gunawardene, S. C., Duffey-Lind, E. C., Lehmann, L., & Diller, L. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.218 · Cited by 104
Self-citationMoreno, L., Rubie, H., Varo, A., Deley, M. L., Amoroso, L., Chevance, A., Garaventa, A., Gambart, M., Bautista, F. J., Valteau‐Couanet, D., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26192 · Cited by 100
Ozkaynak, M. F., Gilman, A. L., London, W. B., Naranjo, A. H., Diccianni, M. B., Tenney, S. C., Smith, M. A., Messer, K. S., Seeger, R. C., Reynolds, C. P., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01355 · Cited by 87
Self-citationDuBois, S. G., Groshen, S. G., Park, J. R., Haas-Kogan, D. A., Yang, X., Geier, E. G., Chen, E., Giacomini, K., Weiss, B., Cohn, S. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3240 · Cited by 75
Self-citationKushner, B. H., Ostrovnaya, I., Cheung, I. Y., Kuk, D., Kramer, K., Modak, S. I., Yataghene, K., & Cheung, N. V. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1016704 · Cited by 62
Seif, A. E., Naranjo, A. H., Baker, D. L., Bunin, N., Kletzel, M., Kretschmar, C., Maris, J. M., McGrady, P., von Allmen, D., Cohn, S. L., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.276 · Cited by 50
Self-citationLong‐term follow‐up of children with high‐risk neuroblastoma: The ENSG5 trial experience
Moreno, L., Vaidya, S. J., Pinkerton, R., Lewis, I. J., Imeson, J., Machin, D., Pearson, A. D. J., & on behalf of the European Neuroblastoma Study Group and the Children's Cancer and Leukaemia Group (CCLG) (formerly UKCCSG) (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24452 · Cited by 47
Meany, H. J., London, W. B., Ambros, P. F., Matthay, K. K., Monclair, T. F., Simon, T., Garaventa, A., Berthold, F., Nakagawara, A., Cohn, S. L., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25134 · Cited by 42
Self-citationKraal, K. C. J. M., Bleeker, G. M., van Eck‐Smit, B. L. F., van Eijkelenburg, N. K. A., Berthold, F., van Noesel, M. M., Caron, H. N., & Tytgat, G. A. M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.013 · Cited by 39
Angiolillo, A. L., Simon, C., Kodish, E., Lange, B., Noll, R. B., Ruccione, K., & Matloub, Y. (2006) · Pediatric Blood & Cancer · doi:10.1002/(issn)1545-5017 · Cited by 36
Cited by
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group
Irwin, M. S., Naranjo, A., Zhang, F. F., Cohn, S. L., London, W. B., Gastier-Foster, J. M., Ramirez, N. C., Pfau, R., Reshmi, S., Wagner, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00278 · Cited by 494
Self-citationAdvancing therapy for neuroblastoma
Qiu, B., & Matthay, K. K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00643-z · Cited by 407
Molecular targeting therapies for neuroblastoma: Progress and challenges
Zafar, A., Wang, W., Liu, G., Wang, X., Xian, W., McKeon, F., Foster, J., Zhou, J., & Zhang, R. (2021) · Medicinal Research Reviews · doi:10.1002/med.21750 · Cited by 380
Kanate, A. S., Majhail, N. S., Savani, B. N., Bredeson, C., Champlin, R. E., Crawford, S., Giralt, S. A., LeMaistre, C. F., Marks, D. I., Omel, J. L., et al. (2020) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2020.03.002 · Cited by 283
Liu, K. X., Naranjo, A., Zhang, F. F., DuBois, S. G., Braunstein, S. E., Voss, S. D., Khanna, G., London, W. B., Doski, J. J., Geiger, J. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03316 · Cited by 60
Self-citation
Metadata
- Authors
- Park, J. R., Kreissman, S. G., London, W. B., Naranjo, A., Cohn, S. L., Hogarty, M. D., Tenney, S. C., Haas-Kogan, D., Shaw, P. J., Kraveka, J. M., Roberts, S. S., Geiger, J. D., Doski, J. J., Voss, S. D., Maris, J. M., Grupp, S. A., & Diller, L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2019-08-27
- Volume
- 322
- Issue
- 8
- Pages
- 746
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2971319283
- Cited by
- 358
- References
- 35
- FWCI
- 21.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.